tiprankstipranks
Anika Therapeutics (CH:AKP)
:AKP
Switzerland Market
AKP
Anika Therapeutics
RESEARCH TOOLSreports

Anika Therapeutics (AKP) Stock Forecast & Price Target

0 Followers
See the Price Targets and Ratings of:

AKP Analyst Ratings

Moderate Buy
2Ratings
Moderate Buy
2 Buy
0 Hold
0 Sell
Based on 2 analysts giving stock ratings to
Anika
Therapeutics
in the past 3 months
TipRanks enables you to focus on the analyst rating consensus of all analysts or only the top performers​ in the past 3 months

AKP Stock 12 Month Forecast

Average Price Target

―
Based on 2 Wall Street analysts offering 12 month price targets for Anika Therapeutics in the last 3 months. The average price target is CHF17.01 with a high forecast of CHF17.01 and a low forecast of CHF17.01. The average price target represents a ― change from the last price of ―.
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
Highest Price TargetCHF17.01Average Price TargetCHF17.01Lowest Price TargetCHF17.01
The highest, average, and lowest price target of all analysts. Click on ‘Top Analysts’ to focus on the best performers.

Detailed List of Analyst Forecasts​

Detailed List of Analyst Forecasts​
Analyst Profile
Expert Firm
Price Target
Position
Upside / Downside
Action
Date
Follow
Article
Barrington Analyst forecast on CH:AKP
Michael Petusky
Barrington
Barrington
CHF13.77→CHF17.01
Buy
―
Reiterated
07/30/26
Anika Therapeutics price target raised to $21 from $17 at BarringtonAnika Therapeutics price target raised to $21 from $17 at Barrington
B. Riley Securities Analyst forecast on CH:AKP
Anderson Schock
B. Riley Securities
B. Riley Securities
CHF14.58→CHF17.01
Buy
―
Reiterated
07/30/26
Anika Therapeutics price target raised to $21 from $18 at B. RileyAnika Therapeutics price target raised to $21 from $18 at B. Riley
Analyst Type
Any
Any
Human Analysts
Ranks
Any
Any
Analyst Rating
Any
Any
Upside/ Downside
Any
Any
Action
Any
Any
Analyst Profile
Expert Firm
Price Target
Position
Upside / Downside
Action
Date
Follow
Article
Barrington Analyst forecast on CH:AKP
Michael Petusky
Barrington
Barrington
CHF13.77→CHF17.01
Buy
―
Reiterated
07/30/26
Anika Therapeutics price target raised to $21 from $17 at BarringtonAnika Therapeutics price target raised to $21 from $17 at Barrington
B. Riley Securities Analyst forecast on CH:AKP
Anderson Schock
B. Riley Securities
B. Riley Securities
CHF14.58→CHF17.01
Buy
―
Reiterated
07/30/26
Anika Therapeutics price target raised to $21 from $18 at B. RileyAnika Therapeutics price target raised to $21 from $18 at B. Riley
Stocks with the Highest Top Analyst Consensus in the Healthcare Sector
AVBPArriVent BioPharma, Inc.
BTSGBrightSpring Health Services, Inc.
AMLXAmylyx Pharmaceuticals Inc
TNYATenaya Therapeutics
JBIOJade Biosciences
Find stocks in the Healthcare sector that are highly recommended by Top Performing Analysts.

Best Analysts Covering Anika Therapeutics

3 Months
Michael PetuskyBarrington
Success Rate
20/29 ratings generated profit
69%
Average Return
+3.37%
Copying Michael Petusky's trades and holding each position for 3 Months would result in 68.97% of your transactions generating a profit, with an average return of +3.37% per trade.
1 Year
Michael PetuskyBarrington
Success Rate
11/29 ratings generated profit
38%
Average Return
+3.59%
Copying Michael Petusky's trades and holding each position for 1 Year would result in 37.93% of your transactions generating a profit, with an average return of +3.59% per trade.
2 Years
Michael PetuskyBarrington
Success Rate
10/29 ratings generated profit
34%
Average Return
+3.19%
Copying Michael Petusky's trades and holding each position for 2 Years would result in 34.48% of your transactions generating a profit, with an average return of +3.19% per trade.
The Best Analyst Covering tool allows you to follow the analysts who have the best success rates and average returns on a specific stock. Only analysts that gave a Buy or Sell rating on the stock in the past 12 months are eligible for inclusion in this tool. Follow the analysts of your choice to receive real-time updates when they publish a new rating.

AKP Analyst Recommendation Trends

Rating
Apr 26
May 26
Jun 26
Jul 26
Aug 26
Strong Buy
0
0
0
0
0
Buy
3
1
1
2
2
Hold
0
0
0
0
0
Sell
0
0
0
0
0
Strong Sell
0
0
0
0
0
total
3
1
1
2
2
In the current month, AKP has received 2 Buy Ratings, 0 Hold Ratings, and 0 Sell Ratings. AKP average Analyst price target in the past 3 months is 17.01.
Each month's total comprises the sum of three months' worth of ratings.

AKP Financial Forecast

AKP Earnings Forecast

Next quarter’s earnings estimate for AKP is CHF0.19 with a range of CHF0.04 to CHF0.34. The previous quarter’s EPS was CHF0.34. AKP beat its EPS estimate ― of the time in the past 12 months, while its overall industry beat the EPS estimate 58.33% of the time in the same period. In the last calendar year AKP has Performed in-line its overall industry.
Next quarter’s earnings estimate for AKP is CHF0.19 with a range of CHF0.04 to CHF0.34. The previous quarter’s EPS was CHF0.34. AKP beat its EPS estimate ― of the time in the past 12 months, while its overall industry beat the EPS estimate 58.33% of the time in the same period. In the last calendar year AKP has Performed in-line its overall industry.

AKP Sales Forecast

Next quarter’s sales forecast for AKP is CHF24.09M with a range of CHF23.82M to CHF24.36M. The previous quarter’s sales results were CHF26.42M. AKP beat its sales estimates ― of the time in past 12 months, while its overall industry beat sales estimates 66.67% of the time in the same period. In the last calendar year AKP has Performed in-line its overall industry.
Next quarter’s sales forecast for AKP is CHF24.09M with a range of CHF23.82M to CHF24.36M. The previous quarter’s sales results were CHF26.42M. AKP beat its sales estimates ― of the time in past 12 months, while its overall industry beat sales estimates 66.67% of the time in the same period. In the last calendar year AKP has Performed in-line its overall industry.

AKP Stock Forecast FAQ

What is CH:AKP’s average 12-month price target, according to analysts?
Based on analyst ratings, Anika Therapeutics’s 12-month average price target is 17.01.
    What is CH:AKP’s upside potential, based on the analysts’ average price target?
    Currently there's no upside potential for CH:AKP, based on the analysts’ average price target.
    Can I see which stocks the top-ranking analysts are rating?
    Yes, go to the Analysts’ Top Stocks tool to see stocks with a Strong Buy or Strong Sell analyst rating consensus, according to the top performers.
      How can I follow the stock ratings of top Wall Street analysts?
      Head over to our Expert Center to see a list of the top 100 Wall Street analysts and follow the analysts of your choice. Visit their profiles for more details about their stock ratings and see how they perform on a stock-by-stock basis.
        Is Anika Therapeutics a Buy, Sell or Hold?
        Anika Therapeutics has a consensus rating of Moderate Buy, which is based on 2 buy ratings, 0 hold ratings and 0 sell ratings.
          What is Anika Therapeutics’s share price target?
          The average share price target for Anika Therapeutics is 17.01. This is based on 2 Wall Streets Analysts 12-month price targets, issued in the past 3 months.
          The highest analyst share price target is CHF17.01 ,and the lowest forecast is CHF17.01. The average share price target represents N/A Increase from the current price of N/A.
            What do analysts say about Anika Therapeutics?
            Anika Therapeutics’s analyst rating consensus is a Moderate Buy. This is based on the ratings of 2 Wall Streets Analysts.
              How can I buy shares of Anika Therapeutics?
              To buy shares of CH:AKP, you can open a brokerage account. See exclusive account opening deals on our Best Online Brokers page.